Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camphoric Acid SCHEMBL12084182 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL2513165 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL30078310 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL23643 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL1738809 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL52395 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL12308 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL7102028 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL12083956 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL27486599 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010656-A | Application of oxyalkylisourea in introducing methyl and isotopically-labeled methyl | 陕西师范大学 | 2026-05-12 | — | — | CN | claimed |
| CN-120136851-A | Preparation method and application of quinoline ester compound | 楚雄师范学院 | 2025-06-13 | — | — | CN | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-116813572-B | Preparation method of camphoric acid formylhydrazine compound, product and application thereof | 南京林业大学 | 2024-03-12 | — | — | CN | claimed |
| CN-116813572-A | Preparation method of camphoric acid formylhydrazine compound, product and application thereof | 南京林业大学 | 2023-09-29 | — | — | CN | claimed |
| CN-112055712-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-07-14 | — | — | CN | claimed |
| CN-116854630-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122010656-A | Application of oxyalkylisourea in introducing methyl and isotopically-labeled methyl | 陕西师范大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-120136851-A | Preparation method and application of quinoline ester compound | 楚雄师范学院 | 2025-06-13 | — | — | CN | disclosed |
| CN-120081755-A | Process for preparing 3- (4' -aminophenyl) -2-methoxypropionic acid and analogues and intermediates thereof | 诺格拉制药有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250115601-A1 | PROCESS FOR THE PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-04-10 | — | — | US | disclosed |
| CN-113825739-B | Process for preparing 3- (4' -aminophenyl) -2-methoxypropionic acid and analogues and intermediates thereof | 诺格拉制药有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4526302-A1 | PROCESS FOR THE PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF | Alivus Life Sciences Limited (IN) | 2025-03-26 | — | — | EP | disclosed |
| EP-4040979-A1 | ANTIMICROBIAL COMPOSITION FOR ANIMAL FEED | Taminco BV (BE) | 2022-08-17 | — | — | EP | disclosed |
| US-8258126-B2 | Vitamin D3 analogues for the prevention and treatment of bone disorders | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20100160455-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2010-06-24 | — | — | US | disclosed |
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160455-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | VDR, CYP24A1, CYP2R1 | ALDH1A1 4226/4885LMNA 531/4885POLB 2845/4885 |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | ALDH1A1 100/4885LMNA 2264/4885POLB 3069/4885 |
| US-20250115601-A1 | PROCESS FOR THE PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF | CYP17A1, HSD17B7, CYP11B1 | ALDH1A1 397/4885LMNA 681/4885POLB 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.